Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.6.1.2 (alanine aminotransferase)
 26,722 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Normotensive, Sprague-Dawley (S-D) and spontaneously hypertensive (SH) rats were subjected to aortic ligature. The systolic blood pressure of S-D rats was increased by +/- 80 mm Hg, whereas the blood pressure of SH rats with pre-existent hypertension increased only slightly, +/- 9 mm Hg. The S-D rats developed myocardial and renal infarcts as well as polyarteritis nodosa; the SH rats developed testicular and microadrenocortical infarcts only. Aortic-ligated S-D rats had elevated creatine phosphokinase, serum glutamic-oxaloacetic transaminase, serum glutamic-pyruvic transaminase, and lactic hydrogenase levels and manifested hyperglycemia, hypercholesterolemia, and elevated blood urea nitrogen (BUN) levels. Corticosterone levels increased in aortic-ligated S-D rats but decreased in SH rats. Collateralization about the site of aortic ligature appeared to be the same in both strains. It is suggested that the acutely induced hypertension in S-D rats rather than SH rats and differences in adrenal steroidogenesis between the two strains would best account for the dichotomous cardiovascular response to aortic constriction.
 ...
PMID:Diverse cardiovascular responses to aortic constriction in normotensive Sprague-Dawley versus spontaneously hypertensive rats. 50 90

Rats and hamsters were fed ETU at levels of 0, 5, 17, 60, 200 mg/kg in the diet. Body weights, food consumption, seric enzyme activities (GPT, alkaline phosphatase), hepatic enzyme activities (GPT, alkaline phosphatase G6PDH), cholesterolemia, thyroid weight and others organs, histology were the criteria studied. ETU was found causing hypercholesterolemia for the 2 species at 5 mg/kg dietary levels. Thyroid impairement is predominant in rat and hepatic impairment is predominant in hamster. ETU was found to be not carcinogenic for hamsters even at 200 mg/kg level and carcinogenic for rats at 60 mg/kg level for males and 200 mg/kg level for females.
 ...
PMID:[Difference in the sensitivity of the hamster and the rat to the effects of long-term administration of ethylenethiourea]. 100 99

Adding less than 0.5% w/w of culture material of strain MRC 826 of the fungus Fusarium moniliforme to a carbohydrate diet low in fat resulted in an atherogenic plasma lipid profile in a non-human primate. Simultaneously increased plasma fibrinogen and activity of blood coagulation factor VII could enhance atherogenesis. This unique potential for promotion of atherosclerosis was probably secondary to chronic hepatotoxicity as indicated by liver fibrosis and elevated cholesterol, albumin and the enzymes AST, ALT, LD, GGT and ALP in serum. The cholesterol and enzymes responded in proportion to the calculated doses of fumonisin mycotoxins in the F. moniliforme MRC 826 cultures. Fumonisins are water soluble and heat stable. Thrombotic, hepatotoxic, carcinogenic and cerebral effects of MRC 826 culture material and fumonisins are well known in non-primates. The estimated fumonisin concentrations tested fall within a range due to natural contamination of human foods. The results suggest that all maize grain products should be analysed for fumonisins.
 ...
PMID:Atherogenic effects in a non-human primate of Fusarium moniliforme cultures added to a carbohydrate diet. 163 55

The inability of the 'ethanol/high vitamin A Lieber-DeCarli diet' to induce liver fibrosis in two different rat strains was further evaluated by determining changes in parameters of liver cell damage and of retinoid and lipid metabolism. In the ethanol/vitamin A-treated group, slight but constant hepatic cell damage, as indicated by elevated alanine aminotransferase, aspartate aminotransferase and glutamate dehydrogenase activities in blood, was already observed at 6 months and maintained until the time of death at 16 months. Serum gamma-glutamyl transaminase activities were not raised. Moderate parenchymal liver cell damage was not accompanied by fibrosis. Hypertriglyceridemia or hypercholesterolemia were observed at 6-16 months of chronic alcohol administration. This response was strain dependent. In ethanol-treated rats of both strains, total liver retinoids and serum retinol concentrations were not altered. Therefore, the hypothesis that interaction between alcohol and retinoids is a major factor in the pathogenesis of alcoholic liver disease, needs to be reconsidered.
 ...
PMID:Chronic administration of ethanol with high vitamin A supplementation in a liquid diet to rats does not cause liver fibrosis. 2. Biochemical observations. 174 28

The hypocholesterolaemic effect of Cassia fistula was investigated using hypercholesterolaemic male albino rats. Hypercholesterolaemia was induced by feeding on a mixture of cholesterol plus cholic acid for a 12 weeks period. Hypercholesterolaemia was characterized by significant increase in the average levels of total lipids, total cholesterol, and triglycerides and significant decrease in phospholipids content. Administration of Cassia fistula significantly reduced blood and liver total lipids. Brain, spleen, kidneys and heart followed nearly the same trend but with moderate effect. Blood, liver, kidneys, spleen and heart total cholesterol was significantly reduced, while that of brain was not affected. The level of triglycerides was markedly improved. There was a moderate rise, however, in phospholipids content in all studied organs. That is to say a marked progress in the correction of lipid metabolism occurred. Also, administration of Cassia fistula induced a significant decrease in the high activities of serum GOT, GPT, alkaline and acid phosphatase and the values nearly returned the initial values. Total serum protein, albumin (A), globulin (G), A/G, free amino acids, uric acid and creatinine were also determined and their values were improved and attained nearly the normal values of the control group.
 ...
PMID:The biochemical role and hypocholesterolaemic potential of the legume Cassia fistula in hypercholesterolaemic rats. 178 5

Male albino rats were fed on a mixture of cholesterol and cholic acid for 12 weeks to induce hypercholesterolemia, then Karkade was administered at 5 and 10% for 9 weeks to evaluate its hypocholesterolemic and hypolipemic effect. The experimental parameters include total lipids, cholesterol, triglycerides and phospholipids. Liver and kidney functions were also investigated in normal, hypo- and hypercholesterolemic rats administered Karkade. A remarkable progress (lowering effect) in the level of different lipid fractions was noticed in spite of the continued cholesterol and cholic acid loading during the treatment. However, blood phospholipids were increased after Karkade administration. Hypercholesterolemia has resulted in an effect on the activity of liver and kidney functions. Therefore, the measurement of serum enzyme activity has provided a useful tool for hepatic recovery. Although the administration of Karkade at 5 and 10% induced a significant decrease in the activity of serum GOT and serum GPT, alkaline and acid phosphatase as well as total serum protein, the values nearly returned to the initial levels after 9 weeks of Karkade administration.
 ...
PMID:Biochemical dynamics and hypocholesterolemic action of Hibiscus sabdariffa (Karkade). 178 44

This randomized, double-blind, multicenter, diet-and-placebo-controlled study was designed to clarify the dose-response relationship of lovastatin therapy to lipid-modifying efficacy and drug-related adverse events. Exclusion criteria were minimized so that study patients were representative of the majority of patients with moderate hypercholesterolemia seen in medical practice. After 6 weeks on the American Heart Association Step 1 Diet, a total of 8,245 patients were randomly assigned to 48 weeks of treatment with diet and placebo or lovastatin at dosages of 20 or 40 mg once a day or 20 or 40 mg twice a day. All adverse events were monitored, with particular attention to evaluation of liver and muscle. Liver transaminase elevations suggestive of possible hepatotoxicity, defined as successive elevations in either aspartate transaminase or alanine aminotransferase greater than 3 times the upper limit of normal, occurred in equal numbers of placebo and lovastatin 20 mg/day treated patients (0.1%). The frequencies were higher in lovastatin 40 mg/day and 80 mg/day patient groups (0.9 and 1.5%, respectively). No patient was diagnosed as having clinically symptomatic hepatic dysfunction. Creatinine kinase (CK) elevations above the upper limit of normal occurred frequently in placebo- (29%), as well as lovastatin-treated patients (29-35%), and muscle symptoms were reported with similar frequency in all groups (7-9%). The combination of muscle symptoms with marked CK elevations (greater than 10 times the upper limit of normal) was seen in only five patients: one in a 40 mg/day dose group and four in the 80 mg/day dose group. No patient developed rhabdomyolysis. The incidence of clinical and laboratory adverse events requiring discontinuation was 6% for the placebo group and from 7% (20 mg/day) to 9% (80 mg/day) for lovastatin treatment groups. No new types of adverse experiences related to lovastatin treatment were reported. Lovastatin, as an adjunct to diet for the reduction of elevated LDL cholesterol, was generally very well tolerated.
 ...
PMID:Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. 183 Oct 6

The authors administered lovastatin (Mevacor, MSD) to 18 patients with primary hyperlipoproteinaemia (familial and non-familial) with a lipoprotein pattern type IIa and IIb. During treatment a marked reduction of atherogenic indicators of the lipid metabolism occurred, i.e. a decline of total cholesterol (-28.6%), LDL-cholesterol -39%), apolipoprotein B (-18.6%), the index of total cholesterol/HDL-cholesterol (-44.6%) and the index LDL-cholesterol/HDL-cholesterol (-48.2%). At the same time a favourable effect on indicators of the lipid metabolism to which a protective action is ascribed was recorded: a rise of HDL-cholesterol (+13.6%) and apolipoprotein AI (+13%) and AII (+13%). An excellent effect was observed also in four heterozygotes with familial hypercholesterolaemia which is usually rather resistant to other types of hypolipidaemic treatment. The drug was very well tolerated and subjective side-effects of treatment were minimal. Despite the fact that a number of laboratory indicators was followed up, the authors did not observe any undesirable side-effects, only a transient and marginal rise of ALT in one patient. Lovastatin is, due to its potent hypolipidaemic effect, a new hope in the treatment of hypercholesterolaemia. Its usefulness in the prevention of ischaemic heart disease, as well as its safety during prolonged administration are tested at present in long-term investigations.
 ...
PMID:[Personal experience with lovastatin, a HMG-CoA reductase inhibitor (Mevacor, MSD) in the treatment of hypercholesterolemia]. 184 44

In the mouse experimental model the effect of two different methods of myeloablation-immunosuppression treatment administered as preparation for bone marrow transplantation was studied, also the effect of animal's age on the values of the essential biochemical parameters in the serum and on the body weight of the animals was assessed. The recipients were prepared for the transplantation with total-body irradiation and administration of cyclophosphamide (radio-chemotherapy) or administration of busulphan with cyclophosphamide (combined chemotherapy). Transplantation was done in animals aged 2.5 and 12 months. In all studied animals serum protein and calcium levels were decreased after the transplantation and the uric acid level was transiently raised. In the older mice a short lasting increase in the serum levels of bilirubin, alkaline phosphatase, AST and ALT was noted. However, no changes were found in the results biochemical investigations which could have been related to the method of myeloablation and immunosuppression, apart from slight hypercholesterolaemia which developed about 30 days after the operation in mice prepared by radio-chemotherapy. However, after a year lower body weight was observed in young mice prepared for the procedure with radiation exposure and cyclophosphamide, as compared to those receiving combined chemotherapy. Clinical aspects of these disturbances are discussed.
 ...
PMID:Values of certain biochemical parameters in mouse serum after syngeneic bone marrow transplantation. Effect of various methods of myeloablation-immunosuppression preparation and recipient's age. 210 62

The effects of simvastatin, an inhibitor of cholesterol synthesis, on serum lipids, lipoprotein composition and apolipoproteins were evaluated in a total of 50 patients with hypercholesterolaemia. In the first study, 24 patients (mean serum cholesterol 10.74 +/- 1.59 mmol/l) were treated with simvastatin 40 mg daily for 24 wk. Serum cholesterol and low density lipoprotein (LDL) cholesterol decreased to average values 29-36% and 35-42% below the basal value, respectively. Serum triglycerides decreased by 16-28%, and high density lipoprotein (HDL) cholesterol increased by 6-11%. Apolipoprotein A-I concentration increased 6-8% and that of apolipoprotein B decreased 29-33%. The composition of LDL remained unchanged whereas the very low density lipoproteins became enriched in triglycerides. Lipoprotein Lp(a) was not affected. In the second study 26 patients (mean serum cholesterol 12.35 +/- 2.05 mmol/l) were treated with simvastatin 40 mg daily as monotherapy or combined with a bile acid binding resin for 2 yr. Serum cholesterol levels decreased to values which remained stable throughout the entire study period; after 2 yr this decrease amounted to 43%. Compared to monotherapy, combination therapy yielded a further 12% decrease of cholesterol. In the entire group, triglycerides decreased by 16% and HDL cholesterol increased by 9%. Side effects were limited to slight increases in alanine aminotransferase and creatine phosphokinase in some patients. Simvastatin appears to be an important asset in the treatment of hypercholesterolaemia.
 ...
PMID:The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia. 235 95


1 2 3 4 5 6 7 8 9 10 Next >>